CML – is difficult to monitor and manage using traditional solutions. New RNA-based assays are hitting the market to make ...

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

The opioid addiction treatment market will be worth $2.4bn by 2033, driven by diagnoses in the eight major world markets.

Based on RNA technology, ICON’s new assay offers huge improvements on how CML is monitored ... NGS assay known as Dup-Seq BCR::ABL1. This innovative assay enables the identification of both ...

Chase Mining Corporation Limited (AU:GCM) has released an update. Chase Mining Corporation Limited has acquired an innovative technology to ...

The McGraw Center is at the heart of efforts to integrate innovative educational technologies into the academic experience. The center encourages the exploration of new media and digital tools in and ...

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...

Their work can help to lower the ... The Evolution of Green Energy Technology: Developing Three-Dimensional Smart Energy Devices With Radiant Cooling and Solar Absorption Oct. 25, 2024 — - DGIST ...

Financial Services Secretary M Nagaraju, who was also present at the ceremony, expressed his happiness with the bank's initiative.

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

Join the CML Book Club! The CTV Morning Live hosts will share a new title each month. Read along, share your thoughts, and recommend your favourite books. The CML Book Club’s first selection is ...